PROBLEM TO BE SOLVED: To provide: agonistic anti-programmed death 1 (PD-1) antibodies to enhance signaling and modulate inflammatory disease and the like of PD-1 protein also known as CD279； and pharmaceuticals containing the anti-PD-1 antibodies.SOLUTION: There is provided a humanized agonistic antibody which binds human PD-1 comprising a variable domain of a heavy chain with a specific sequence and a variable domain of a light chain with a specific sequence, in which the variable domains are transferred to a human antibody framework from a murine monoclonal antibody which binds the human PD-1. In a humanized agonistic antibody which binds human PD-1 comprising a heavy chain, a heavy chain framework region is preferably derived from human sub-group sequence VH 1-3 1-4+JH (from a specific sequence).SELECTED DRAWING: None【課題】ＣＤ２７９としても知られるプログラム死１（ＰＤ－１）タンパクのシグナル伝達を増強し炎症性疾患等を調節するためのアゴニスト抗ＰＤ－１抗体、並びに抗ＰＤ－１抗体を含む薬剤の提供。【解決手段】特定の配列を持つ重鎖の可変ドメイン、並びに特定の配列を持つ軽鎖の可変ドメインを含むヒトＰＤ－１に結合するマウスモノクローナル抗体より、該可変ドメインをヒト抗体フレームワークに移植したヒトＰＤ－１に結合するヒト化アゴニスト抗体。重鎖を含む、ヒトＰＤ－１に結合するヒト化アゴニスト抗体であって、重鎖のフレームワーク領域がヒト下位集団配列ＶＨ １－３ １－４＋ＪＨ（特定配列由来）であることが好ましいヒト化アゴニスト抗体。【選択図】なし
